DCM
CLDI icon

Driehaus Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Driehaus Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-789
Closed -$18.9K – 394
2024
Q2 		$18.9K Hold
789
– – ﹤0.01% 361
2024
Q1 		$53.5K Hold
789
– – ﹤0.01% 378
2023
Q4 		$143K Hold
789
– – ﹤0.01% 378
2023
Q3 		$360K Buy
789
+221
+39% +$224K ﹤0.01% 362
2023
Q2 		$715K Hold
568
– – 0.01% 323
2023
Q1 		$700K Hold
568
– – 0.01% 335
2022
Q4 		$693K Sell
568
-7,765
-93% -$9.3M 0.01% 307
2022
Q3 		$9.85M Sell
8,333
-4,167
-33% -$4.99M 0.15% 193
2022
Q2 		$14.9M Hold
12,500
– – 0.24% 142
2022
Q1 		$14.8M Hold
12,500
– – 0.18% 175
2021
Q4 		$14.7M Buy
+12,500
New +$14.7M 0.15% 192

Other funds holding CLDI

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $559M AUM 19.86% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Driehaus Capital Management's CLDI Position: Q3 2024 in Review

Driehaus Capital Management sold out of Calidi Biotherapeutics (CLDI) in Q3 2024, closing a stake of 789 shares — an estimated $18.9K sold.

Driehaus Capital Management first reported a position in CLDI in Q4 2021 and held it in 11 quarters. The position peaked at $14.9M in Q2 2022. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2024.

  • Driehaus Capital Management reported no remaining Calidi Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Driehaus Capital Management sold 789 Calidi Biotherapeutics shares in Q3 2024, an estimated $18.9K.
  • Driehaus Capital Management first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 11 quarters.
  • Driehaus Capital Management's Calidi Biotherapeutics position peaked at $14.9M in Q2 2022.
  • 20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2024.

Based on Driehaus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.